Ligand Pharm (LGND)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2005 | 12-2004 | 12-2003 | 12-2002 | 12-2001 | |
| Sales | 10,217 | 112,112 | 81,118 | 71,769 | 76,341 |
| Cost of Goods | N/A | 18,264 | 26,557 | 14,738 | 13,947 |
| Gross Profit | 10,217 | 93,848 | 54,561 | 57,031 | 62,394 |
| Operating Expenses | 53,844 | 109,492 | 129,135 | 101,623 | 86,478 |
| Operating Income | -43,627 | -15,380 | -74,017 | -43,854 | -23,137 |
| Interest Expense | 1,306 | 12,006 | 11,142 | 6,295 | 13,601 |
| Other Income | 2,589 | 4,801 | -9,251 | -2,064 | -6,257 |
| Pre-tax Income | -42,344 | -22,585 | -94,410 | -52,213 | -42,995 |
| Income Tax | -6,309 | 179 | 56 | 44 | N/A |
| Net Income Continuous | -36,035 | -22,764 | -94,466 | -52,257 | -42,995 |
| Net Income Discontinuous | -364 | -22,377 | N/A | N/A | N/A |
| Net Income | $-36,399 | $-45,141 | $-96,471 | $-52,257 | $-42,995 |
| EPS Basic Total Ops | -2.94 | -3.66 | -8.16 | -4.56 | -4.32 |
| EPS Basic Continuous Ops | -2.94 | -1.86 | -7.98 | -4.56 | -4.32 |
| EPS Basic Discontinuous Ops | -0.03 | -1.80 | N/A | N/A | N/A |
| EPS Diluted Total Ops | -2.94 | -3.66 | -8.16 | -4.56 | -4.32 |
| EPS Diluted Continuous Ops | -2.94 | -1.86 | -7.98 | -4.56 | -4.32 |
| EPS Diluted Discontinuous Ops | -0.03 | -1.80 | N/A | N/A | N/A |
| EBITDA(a) | $-24,920 | $-105 | $-59,689 | $-35,131 | $-7,576 |